

**From:** [OC GCP Questions](#)  
**To:** [Redacted]  
**Subject:** Question about Adverse event  
**Date:** Wednesday, March 26, 2014 8:19:38 AM

---

Good morning –

As stated below, the protocol should dictate what should be recorded as an AE. If you are not the sponsor, please also consult the sponsor of your study. However, if you can clearly document that the condition existed prior to enrollment in the study than it would seem that documenting it in the clinical history might seem appropriate. If your study is under an IND with FDA you can always consult the review division that is overseeing your study for more specific advice.

Kind regards,

Doreen M. Kezer, MSN  
Senior Health Policy Analyst  
Office of Good Clinical Practice  
Office of the Commissioner, FDA

This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

---

**From:** FYXUMXQ  
**Sent:** Tuesday, March 25, 2014 11:31 AM  
**To:** OC GCP Questions  
**Subject:** RE: Question about Adverse event

Hi,

Thanks for your answer, however the question was more focused on how to classify those pathology that are discovered during the study but are clearly there from long before the study.

Should we report as AE or clinical History?

[Redacted]